Skip to main content
Top
Published in: Current Hepatology Reports 2/2017

01-06-2017 | Hepatitis B (J Lim, Section Editor)

Ethnic Disparities in Chronic Hepatitis B Infection: African Americans and Hispanic Americans

Author: Kimberly A. Forde

Published in: Current Hepatology Reports | Issue 2/2017

Login to get access

Abstract

Purpose of Review

Chronic infection with hepatitis B affects more than 240 million persons worldwide and is a major public health concern. Despite national and global initiatives to promote hepatitis B elimination, including newborn vaccination, catch-up vaccination in adolescents and high-risk adults, screening of the blood supply, and treatment of those in need, both new infections and a reservoir of chronic infections continue to result in morbidity and mortality. As with many chronic diseases, racial and ethnic disparities are seen in hepatitis B virus infection. The goal of this review is to synthesize the data concerning the burden of hepatitis B infection in African Americans and Hispanics, two racial/ethnic groups in the United States who encounter barriers in access to care, low engagement in care, and low utilization of diagnostic and treatment services.

Recent Findings

Recent data, though sparse in certain areas, continue to suggest differences in rates of incidence and prevalence of hepatitis B virus infection in African Americans, and differences in screening, specialty referral and initiation of therapy for African Americans and Hispanics. Data are lacking about differences in liver disease progression and manifestations in both African Americans and Hispanics.

Summary

Disparities in hepatitis B diagnosis, disease management, treatment, and prevention remain for African Americans and Hispanics. These disparities require a commitment from governmental and public health organizations. The efforts should include increasing vaccination in those most susceptible to infection, screening those at highest risk for infection, initiating antiviral therapy in those who require it, and monitoring for liver-related complications, such as decompensated cirrhosis and hepatocellular carcinoma in the chronically infected. This multipronged approach is necessary to realize hepatitis B elimination.
Literature
2.
go back to reference G. B. D. Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71. doi:10.1016/S0140-6736(14)61682-2.CrossRef G. B. D. Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71. doi:10.​1016/​S0140-6736(14)61682-2.CrossRef
4.
go back to reference Transforming our world: the 2030 agenda for sustainable development. In: Seventieth United Nations General Assembly, New York, 15 September 2015–13 September 2016, (2016). Transforming our world: the 2030 agenda for sustainable development. In: Seventieth United Nations General Assembly, New York, 15 September 2015–13 September 2016, (2016).
5.
go back to reference Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010;202(2):192–201. doi:10.1086/653622.CrossRefPubMed Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010;202(2):192–201. doi:10.​1086/​653622.CrossRefPubMed
7.
go back to reference Kowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology. 2012;56(2):422–33. doi:10.1002/hep.24804.CrossRefPubMed Kowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology. 2012;56(2):422–33. doi:10.​1002/​hep.​24804.CrossRefPubMed
8.
go back to reference Roberts H, Kruszon-Moran D, Ly KN, Hughes E, Iqbal K, Jiles RB, et al. Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988–2012. Hepatology. 2016;63(2):388–97. doi:10.1002/hep.28109.CrossRefPubMed Roberts H, Kruszon-Moran D, Ly KN, Hughes E, Iqbal K, Jiles RB, et al. Prevalence of chronic hepatitis B virus (HBV) infection in U.S. households: National Health and Nutrition Examination Survey (NHANES), 1988–2012. Hepatology. 2016;63(2):388–97. doi:10.​1002/​hep.​28109.CrossRefPubMed
9.
go back to reference Buckley GJ, Strom BL. A national strategy for the elimination of viral hepatitis emphasizes prevention, screening, and universal treatment of hepatitis C. Ann Intern Med. 2017; doi:10.7326/M17-0766.PubMed Buckley GJ, Strom BL. A national strategy for the elimination of viral hepatitis emphasizes prevention, screening, and universal treatment of hepatitis C. Ann Intern Med. 2017; doi:10.​7326/​M17-0766.PubMed
10.
go back to reference Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep. 1991;40(RR-13): 1–25. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep. 1991;40(RR-13): 1–25.
11.
go back to reference Centers for Disease Control and Prevention. Postexposure prophylaxis of hepatitis B. MMWR Morb Mortal Wkly Rep. 1984;33(21):285–90. Centers for Disease Control and Prevention. Postexposure prophylaxis of hepatitis B. MMWR Morb Mortal Wkly Rep. 1984;33(21):285–90.
14.
go back to reference McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health. 1999;89(1):14–8.CrossRefPubMedPubMedCentral McQuillan GM, Coleman PJ, Kruszon-Moran D, Moyer LA, Lambert SB, Margolis HS. Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health. 1999;89(1):14–8.CrossRefPubMedPubMedCentral
15.
go back to reference Reid A. Viral hepatitis in African Americans. Current Hepatitis Reports. 2008;7:120–6.CrossRef Reid A. Viral hepatitis in African Americans. Current Hepatitis Reports. 2008;7:120–6.CrossRef
16.
go back to reference Kuo I, Sherman SG, Thomas DL, Strathdee SA. Hepatitis B virus infection and vaccination among young injection and non-injection drug users: missed opportunities to prevent infection. Drug Alcohol Depend. 2004;73(1):69–78.CrossRefPubMed Kuo I, Sherman SG, Thomas DL, Strathdee SA. Hepatitis B virus infection and vaccination among young injection and non-injection drug users: missed opportunities to prevent infection. Drug Alcohol Depend. 2004;73(1):69–78.CrossRefPubMed
17.
go back to reference MacKellar DA, Valleroy LA, Secura GM, McFarland W, Shehan D, Ford W, et al. Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men. Am J Public Health. 2001;91(6):965–71.CrossRefPubMedPubMedCentral MacKellar DA, Valleroy LA, Secura GM, McFarland W, Shehan D, Ford W, et al. Two decades after vaccine license: hepatitis B immunization and infection among young men who have sex with men. Am J Public Health. 2001;91(6):965–71.CrossRefPubMedPubMedCentral
18.
go back to reference Goldstein ST, Alter MJ, Williams IT, Moyer LA, Judson FN, Mottram K, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982–1998: implications for vaccination programs. J Infect Dis. 2002;185(6):713–9. doi:10.1086/339192.CrossRefPubMed Goldstein ST, Alter MJ, Williams IT, Moyer LA, Judson FN, Mottram K, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982–1998: implications for vaccination programs. J Infect Dis. 2002;185(6):713–9. doi:10.​1086/​339192.CrossRefPubMed
22.
go back to reference Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401. doi:10.1038/nature08309.CrossRefPubMed Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401. doi:10.​1038/​nature08309.CrossRefPubMed
24.
go back to reference Hu CC, Lin CL, Chang LC, Chien CH, Chen LW, Liu CJ, et al. Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study. BMC Infect Dis. 2015;15:156. doi:10.1186/s12879-015-0888-x.CrossRefPubMedPubMedCentral Hu CC, Lin CL, Chang LC, Chien CH, Chen LW, Liu CJ, et al. Interleukin-28B gene non-TT allele strongly predicts treatment failure for genotype 1 infected chronic hepatitis C patients with advanced fibrosis: a case control study. BMC Infect Dis. 2015;15:156. doi:10.​1186/​s12879-015-0888-x.CrossRefPubMedPubMedCentral
26.
go back to reference Hu DJ, Xing J, Tohme RA, Liao Y, Pollack H, Ward JW, et al. Hepatitis B testing and access to care among racial and ethnic minorities in selected communities across the United States, 2009–2010. Hepatology. 2013;58(3):856–62. doi:10.1002/hep.26286.CrossRefPubMed Hu DJ, Xing J, Tohme RA, Liao Y, Pollack H, Ward JW, et al. Hepatitis B testing and access to care among racial and ethnic minorities in selected communities across the United States, 2009–2010. Hepatology. 2013;58(3):856–62. doi:10.​1002/​hep.​26286.CrossRefPubMed
27.
go back to reference Jeffers L, Van Rensburg CJ, Banks A, Schechter M, Schmidt SJ, Hu W, et al. Antiviral efficacy of entecavir in nucleos(t)ide-naive patients of Black/African descent with chronic hepatitis B. J Viral Hepat. 2014;21(1):74–6. doi:10.1111/jvh.12144.CrossRefPubMed Jeffers L, Van Rensburg CJ, Banks A, Schechter M, Schmidt SJ, Hu W, et al. Antiviral efficacy of entecavir in nucleos(t)ide-naive patients of Black/African descent with chronic hepatitis B. J Viral Hepat. 2014;21(1):74–6. doi:10.​1111/​jvh.​12144.CrossRefPubMed
29.
go back to reference Campsen J, Zimmerman M, Trotter J, Hong J, Freise C, Brown RS Jr, et al. Multicenter review of liver transplant for hepatitis B-related liver disease: disparities in gender and ethnicity. Clin Transpl. 2013;27(6):829–37. doi:10.1111/ctr.12224.CrossRef Campsen J, Zimmerman M, Trotter J, Hong J, Freise C, Brown RS Jr, et al. Multicenter review of liver transplant for hepatitis B-related liver disease: disparities in gender and ethnicity. Clin Transpl. 2013;27(6):829–37. doi:10.​1111/​ctr.​12224.CrossRef
31.
go back to reference Dominguez K, Penman-Aguilar A, Chang MH, Moonesinghe R, Castellanos T, Rodriguez-Lainz A, et al. Vital signs: leading causes of death, prevalence of diseases and risk factors, and use of health services among Hispanics in the United States—2009–2013. MMWR Morb Mortal Wkly Rep. 2015;64(17):469–78.PubMed Dominguez K, Penman-Aguilar A, Chang MH, Moonesinghe R, Castellanos T, Rodriguez-Lainz A, et al. Vital signs: leading causes of death, prevalence of diseases and risk factors, and use of health services among Hispanics in the United States—2009–2013. MMWR Morb Mortal Wkly Rep. 2015;64(17):469–78.PubMed
32.
go back to reference Setiawan VW, Stram DO, Porcel J, Lu SC, Le Marchand L, Noureddin M. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort. Hepatology. 2016;64(6):1969–77. doi:10.1002/hep.28677.CrossRefPubMed Setiawan VW, Stram DO, Porcel J, Lu SC, Le Marchand L, Noureddin M. Prevalence of chronic liver disease and cirrhosis by underlying cause in understudied ethnic groups: the multiethnic cohort. Hepatology. 2016;64(6):1969–77. doi:10.​1002/​hep.​28677.CrossRefPubMed
33.
go back to reference Setiawan VW, Hernandez BY, Lu SC, Stram DO, Wilkens LR, Le Marchand L, et al. Diabetes and racial/ethnic differences in hepatocellular carcinoma risk: the multiethnic cohort. J Natl Cancer Inst. 2014;106(12) doi:10.1093/jnci/dju326. Setiawan VW, Hernandez BY, Lu SC, Stram DO, Wilkens LR, Le Marchand L, et al. Diabetes and racial/ethnic differences in hepatocellular carcinoma risk: the multiethnic cohort. J Natl Cancer Inst. 2014;106(12) doi:10.​1093/​jnci/​dju326.
35.
go back to reference Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among children aged 19–35 months—United States, 2008. MMWR Morb Mortal Wkly Rep. 2009;58(33):921–6. Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among children aged 19–35 months—United States, 2008. MMWR Morb Mortal Wkly Rep. 2009;58(33):921–6.
36.
go back to reference Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among children aged 19–35 months—United States, 2009. MMWR Morb Mortal Wkly Rep. 2010;59(36):1171–7. Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among children aged 19–35 months—United States, 2009. MMWR Morb Mortal Wkly Rep. 2010;59(36):1171–7.
37.
go back to reference Centers for Disease Control and Prevention. Hepatitis A vaccination coverage among children aged 24–35 months—United States, 2003. MMWR Morb Mortal Wkly Rep. 2005;54(6):141–4. Centers for Disease Control and Prevention. Hepatitis A vaccination coverage among children aged 24–35 months—United States, 2003. MMWR Morb Mortal Wkly Rep. 2005;54(6):141–4.
38.
go back to reference Centers for Disease Control and Prevention. Hepatitis B vaccination coverage among adults—United States, 2004. MMWR Morb Mortal Wkly Rep. 2006;55(18):509–11. Centers for Disease Control and Prevention. Hepatitis B vaccination coverage among adults—United States, 2004. MMWR Morb Mortal Wkly Rep. 2006;55(18):509–11.
39.
go back to reference McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med. 2005;142(5):333–41.CrossRefPubMed McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O, et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med. 2005;142(5):333–41.CrossRefPubMed
40.
go back to reference McMahon BJ, Dentinger CM, Bruden D, Zanis C, Peters H, Hurlburt D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis. 2009;200(9):1390–6. doi:10.1086/606119.CrossRefPubMed McMahon BJ, Dentinger CM, Bruden D, Zanis C, Peters H, Hurlburt D, et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis. 2009;200(9):1390–6. doi:10.​1086/​606119.CrossRefPubMed
41.
go back to reference Centers for Disease Control and Prevention. Adult vaccination coverage—United States, 2010. MMWR Morb Mortal Wkly Rep. 2012;61(4):66–72. Centers for Disease Control and Prevention. Adult vaccination coverage—United States, 2010. MMWR Morb Mortal Wkly Rep. 2012;61(4):66–72.
42.
go back to reference Williams WW, Lu PJ, O'Halloran A, Kim DK, Grohskopf LA, Pilishvili T, et al. Surveillance of vaccination coverage among adult populations—United States, 2014. MMWR Surveill Summ. 2016;65(1):1–36. doi:10.15585/mmwr.ss6501a1.CrossRefPubMed Williams WW, Lu PJ, O'Halloran A, Kim DK, Grohskopf LA, Pilishvili T, et al. Surveillance of vaccination coverage among adult populations—United States, 2014. MMWR Surveill Summ. 2016;65(1):1–36. doi:10.​15585/​mmwr.​ss6501a1.CrossRefPubMed
44.
go back to reference Hechter RC, Jacobsen SJ, Luo Y, Nomura JH, Towner WJ, Tartof SY, et al. Hepatitis B testing and vaccination among adults with sexually transmitted infections in a large managed care organization. Clin Infect Dis. 2014;58(12):1739–45. doi:10.1093/cid/ciu103.CrossRefPubMed Hechter RC, Jacobsen SJ, Luo Y, Nomura JH, Towner WJ, Tartof SY, et al. Hepatitis B testing and vaccination among adults with sexually transmitted infections in a large managed care organization. Clin Infect Dis. 2014;58(12):1739–45. doi:10.​1093/​cid/​ciu103.CrossRefPubMed
46.
go back to reference Institute of Medicine. Hepatitis and liver cancer: a national strategy for prevention of hepatitis B and C. Washington, DC: The National Academies Press; 2010. Institute of Medicine. Hepatitis and liver cancer: a national strategy for prevention of hepatitis B and C. Washington, DC: The National Academies Press; 2010.
48.
go back to reference Pollack H, Wang S, Wyatt L, Peng CH, Wan K, Trinh-Shevrin C, et al. A comprehensive screening and treatment model for reducing disparities in hepatitis B. Health Aff (Millwood). 2011;30(10):1974–83. doi:10.1377/hlthaff.2011.0700.CrossRef Pollack H, Wang S, Wyatt L, Peng CH, Wan K, Trinh-Shevrin C, et al. A comprehensive screening and treatment model for reducing disparities in hepatitis B. Health Aff (Millwood). 2011;30(10):1974–83. doi:10.​1377/​hlthaff.​2011.​0700.CrossRef
49.
Metadata
Title
Ethnic Disparities in Chronic Hepatitis B Infection: African Americans and Hispanic Americans
Author
Kimberly A. Forde
Publication date
01-06-2017
Publisher
Springer US
Published in
Current Hepatology Reports / Issue 2/2017
Electronic ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-017-0348-8

Other articles of this Issue 2/2017

Current Hepatology Reports 2/2017 Go to the issue

Autoimmune, Cholestatic, and Biliary Diseases (S Gordon and C Bowlus, Section Editors)

Are Dominant Strictures in Primary Sclerosing Cholangitis a Risk Factor for Cholangiocarcinoma?

Autoimmune, Cholestatic, and Biliary Diseases (S Gordon and C Bowlus, Section Editors)

Autoimmune Hepatitis: When Is It Safe to Stop Therapy, or Withhold Therapy Altogether?

Autoimmune, Cholestatic, and Biliary Diseases (S Gordon and C Bowlus, Section Editors)

The Causes and Clinical Spectrum of Drug-Induced Cholestatic Liver Injury

Hepatic Cancer (A Singal and A Mufti, Section Editors)

Should AFP (or Any Biomarkers) Be Used for HCC Surveillance?

Hepatic Cancer (A Singal and A Mufti, Section Editors)

Multidisciplinary Team Management of Patients with Hepatocellular Carcinoma

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.